Horse Deaths Raise Drug Safety Concerns

Critic points to a lack of federal oversight for drug compounding.

ByABC News
April 24, 2009, 10:38 AM

April 24, 2009— -- The shocking disclosure that a pharmacy error may have caused the deaths of 21 prized polo horses has prompted drug safety advocates to renew their calls for more oversight of what they say is a largely unregulated sector of the pharmaceutical industry.

The horse deaths are the latest to be linked to 'compounding,' a practice that traditionally involves pharmacists mixing or changing FDA approved medications to create medications for unique patient needs, such as creating a syrup for children who cannot swallow pills.

As the business of large-scale compounding emerged over the past decade, drug safety experts have raised concerns that these pharmacies may be manufacturing drugs outside of the oversight of the Food and Drug Administration.

"Compounding is this shadow industry that has been operating outside the public's periscope," said Larry Sasich, pharmacist and an assistant professor at the Lake Erie College of Medicine. "Consumers don't know that these products are not FDA-approved."

In 2007, investigators in Oregon determined that errors in compounded medications caused at least two deaths after a Texas pharmacy supplied an alternative medicine clinic with doses of a drug that was eight times the standard level, according to an article published in the Journal of the American Medical Association.

The drug, an intraveous form of colchicine, was being used by the clinic to treat back pain, a use that had not been approved by the FDA.

L.D. King, a spokeperson for the International Academy of Compounding Pharmacists, said in a statement that compounding pharmacists are "strictly regulated at the state level," where regulators are "in the best position to inspect local pharamacy operations, develop appropriate regulations, and respond to any problems that may arise."

Sasich says that state regulators often lack the resources for adequate enforcement, and find it difficult to investigate compounders who supply drugs across state lines. Public health officials have also raised concerns that the patchwork of state-by-state oversight makes it difficult to judge the full extent of any threat to public health and safety.